Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22966404 | 0.98 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL14524817 | 0.98 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL3413831 | 0.98 | ALDH1A1 (0.50) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL12206787 | 0.95 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL4086161 | 0.90 | ALDH1A1 (0.54) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL25161958 | 0.86 | ALDH1A1 (0.47) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL25162021 | 0.84 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 | |
| SCHEMBL6840504 | 0.82 | ALDH1A1 (0.49) | ALDH1A1POLBCYP3A4CYP2D6PKM | |
| SCHEMBL22354451 | 0.82 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL14328665 | 0.82 | ALDH1A1 (0.49) | ALDH1A1POLBSMN1; SMN2GAACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SHENZHEN MAGICRNA BIOTECHNOLOGY CO LTD (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-09-23 | — | — | US | disclosed |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-08-05 | — | — | US | disclosed |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2021-05-04 | — | — | US | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-7803836-B2 | Aminophenylsulfonamide derivatives as HIV protease inhibitor | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-09-28 | — | — | US | disclosed |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ALMIRALL, S.A. (ES) | 2010-09-16 | — | — | US | disclosed |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249084-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ALDH1A1 381/4885POLB 1465/4885SMN1; SMN2 2600/4885 |
| US-20210236442-A1 | METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES | IAPP, SLC5A2, SLC2A2 | ALDH1A1 3985/4885POLB 823/4885SMN1; SMN2 855/4885 |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | FURIN, PEPD, PIN1 | ALDH1A1 4014/4885POLB 1078/4885SMN1; SMN2 1122/4885 |
| US-20230348360-A1 | Amino Lipid and Preparation Method and Application Thereof | SLC7A1, SLC7A5, SLC43A1 | ALDH1A1 2776/4885POLB 1786/4885SMN1; SMN2 2084/4885 |
| US-10993938-B2 | Lactam compound, preparation method and use thereof | FURIN, PEPD, PIN1 | ALDH1A1 4014/4885POLB 1078/4885SMN1; SMN2 1122/4885 |
| US-20100234341-A1 | SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA3, ADORA1, ADORA2A | ALDH1A1 360/4885POLB 956/4885SMN1; SMN2 3181/4885 |
| US-20110142798-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | ALDH1A1 365/4885POLB 682/4885SMN1; SMN2 4162/4885 |
| US-20100226883-A1 | LINKED DIIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | ALDH1A1 229/4885POLB 538/4885SMN1; SMN2 3298/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | ALDH1A1 378/4885POLB 931/4885SMN1; SMN2 1639/4885 |
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | ALDH1A1 1037/4885POLB 2949/4885SMN1; SMN2 4884/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | ALDH1A1 287/4885POLB 397/4885SMN1; SMN2 3515/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | ALDH1A1 2605/4885POLB 3278/4885SMN1; SMN2 3203/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ALDH1A1 1235/4885POLB 3763/4885SMN1; SMN2 2041/4885 |
| US-20210290623-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | ALDH1A1 1235/4885POLB 3763/4885SMN1; SMN2 2041/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | ALDH1A1 132/4885POLB 460/4885SMN1; SMN2 3511/4885 |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | DNPEP, NPEPPS, ANPEP | ALDH1A1 3182/4885POLB 1710/4885SMN1; SMN2 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.